Joint wear is common and can cause pain, limited movement and reduced quality of life. Traditional treatments can be complicated and involve lengthy recovery. ChondroFiller offers a simpler, non-surgical route: a single liquid collagen injection. This article explains how it works, with realistic expectations throughout.
Why Joint Wear Is Hard to Manage
Cartilage cushions the joints, but it has a very limited ability to heal itself because it lacks a direct blood supply. Surgical approaches such as microfracture involve an operation and recovery, and results can vary — which is why non-surgical options are of interest to many patients and clinicians.
ChondroFiller: A Liquid Gel, in a Single Step
ChondroFiller is a Class III CE-marked medical device: a liquid gel made largely from purified type I collagen, manufactured by Meidrix Biomedicals in Germany. It is delivered into the joint as a single, non-surgical injection — no cell harvesting and no operation. The device is acellular (cell-free); once inside the joint, it self-gels within a few minutes and may settle over worn surfaces, adding a protective collagen layer that helps cushion the joint and reduce grinding. It recruits the patient's own progenitor cells to support cartilage repair over time.
What Makes It Stand Out
ChondroFiller is delivered without open surgery: using an ultrasound-guided injection, the clinician guides a fine needle accurately into the joint. The benefits include a short procedure, no incision, less disturbance to surrounding tissue and a reduced risk of complications, with a prompt return to normal activities. Published clinical data demonstrate improvements in pain and function across several joints, though responses vary between individuals.
It is collagen-based with biological potential, but it is best understood as a supportive, joint-preserving injection — not a guaranteed repair, cure or reversal of arthritis. Patients with advanced disease or larger defects may require a different approach, and a thorough clinical assessment is always needed to determine suitability.
What the Evidence Shows
Clinical experience with ChondroFiller supports its use for ICRS Grade I–IV cartilage defects in a range of joints. In published series, International Knee Documentation Committee (IKDC) scores have improved by approximately 30 points over 12–36 months in knee cases. Hip outcomes, assessed by modified Harris Hip Scores, show comparable gains. A 2023 study in thumb-base osteoarthritis reported improvements in pain and grip strength (Corain et al., 2023), though responses vary. MRI evaluation using MOCART scoring has confirmed cartilage defect fill in multiple studies. The device has a strong safety profile; across a large number of units sold since 2013, the reported serious-incident rate has been very low.
Conclusion
ChondroFiller offers a non-surgical, single-step liquid collagen injection that may help support a worn joint and ease symptoms for some people, with less disruption than surgery. At the London Cartilage Clinic, patients can receive a thorough assessment to explore whether the ChondroFiller injection or another approach best suits their situation. For tailored guidance, consult a qualified healthcare professional.
References
Corain, M., Zanotti, F., Giardini, M., Gasperotti, L., Invernizzi, E., Biasi, V., & Lavagnolo, U. (2023). The use of an acellular collagen matrix ChondroFiller Liquid for trapeziometacarpal osteoarthritis. Cartilage.
Frequently Asked Questions
- It is a non-surgical, single-step liquid collagen injection that may add a protective, cushioning layer over worn joint surfaces — no cell harvesting and no operation. It is a CE-marked Class III medical device, not a cure, and is best understood as a joint-preserving biological scaffold.
- Clinical experience suggests it may suit patients with ICRS Grade I–IV cartilage defects in accessible joints where the lesion size and location allow accurate ultrasound-guided delivery. A full clinical assessment is needed to determine suitability; patients with advanced joint disease or very large defects may be better served by other approaches.
- The collagen gel self-sets within a few minutes inside the joint. Recovery is generally prompt compared with surgical alternatives, and patients are usually advised on a short period of reduced loading before returning to normal activity. Individual recovery timelines vary.
- A short, non-surgical injection with no incision, less disturbance to tissue and prompt return to normal activities. Published series report meaningful improvements in pain and function scores across several joints, though benefits vary and cannot be guaranteed.
- No. ChondroFiller is the CE-marked collagen scaffold device, and the ChondroFiller injection is a non-surgical, ultrasound-guided outpatient procedure. Liquid Cartilage refers to the Lee Liquid Cartilage Protocol — a separate, keyhole surgical procedure developed at the London Cartilage Clinic that places ChondroFiller arthroscopically alongside biological adjuncts and, where indicated, the patient's own stem cells. They are distinct pathways suited to different clinical situations.
Where to go from here
A few next steps tailored to what you have just read.
Legal & Medical Disclaimer
This article is written by an independent contributor and reflects their own views and experience, not necessarily those of London Cartilage Clinic. It is provided for general information and education only and does not constitute medical advice, diagnosis, or treatment.
Always seek personalised advice from a qualified healthcare professional before making decisions about your health. London Cartilage Clinic accepts no responsibility for errors, omissions, third-party content, or any loss, damage, or injury arising from reliance on this material.
If you believe this article contains inaccurate or infringing content, please contact us at [email protected].
